Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

L Tonneijck; MM Smits; MHA Muskiet; T Hoekstra; MHH Kramer; Jan Danser; PM ter Wee; M Diamant; JA Joles; DH van Raalte

doi:10.2337/dc16-1371

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

L Tonneijck
, MM Smits
, MHA Muskiet
, T Hoekstra
, MHH Kramer
, Jan Danser
, PM ter Wee
, M Diamant
, JA Joles
, DH van Raalte

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

100 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2042-2050
Number of pages	9
Journal	Diabetes Care
Volume	39
Issue number	11
DOIs	https://doi.org/10.2337/dc16-1371
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC COEUR-09
EMC COEUR-09-39-02

Access to Document

10.2337/dc16-1371

Cite this

Tonneijck, L., Smits, MM., Muskiet, MHA., Hoekstra, T., Kramer, MHH., Danser, J., ter Wee, PM., Diamant, M., Joles, JA., & van Raalte, DH. (2016). Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care, 39(11), 2042-2050. https://doi.org/10.2337/dc16-1371

@article{c23117c81ea3461db309fd5fc8924b61,

title = "Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial",

author = "L Tonneijck and MM Smits and MHA Muskiet and T Hoekstra and MHH Kramer and Jan Danser and \{ter Wee\}, PM and M Diamant and JA Joles and \{van Raalte\}, DH",

year = "2016",

doi = "10.2337/dc16-1371",

language = "Undefined/Unknown",

volume = "39",

pages = "2042--2050",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "11",

}

Tonneijck, L, Smits, MM, Muskiet, MHA, Hoekstra, T, Kramer, MHH, Danser, J, ter Wee, PM, Diamant, M, Joles, JA & van Raalte, DH 2016, 'Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial', Diabetes Care, vol. 39, no. 11, pp. 2042-2050. https://doi.org/10.2337/dc16-1371

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. / Tonneijck, L; Smits, MM; Muskiet, MHA et al.
In: Diabetes Care, Vol. 39, No. 11, 2016, p. 2042-2050.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

AU - Tonneijck, L

AU - Smits, MM

AU - Muskiet, MHA

AU - Hoekstra, T

AU - Kramer, MHH

AU - Danser, Jan

AU - ter Wee, PM

AU - Diamant, M

AU - Joles, JA

AU - van Raalte, DH

PY - 2016

Y1 - 2016

U2 - 10.2337/dc16-1371

DO - 10.2337/dc16-1371

M3 - Article

C2 - 27585605

SN - 0149-5992

VL - 39

SP - 2042

EP - 2050

JO - Diabetes Care

JF - Diabetes Care

IS - 11

ER -